• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    11/14/24 5:49:49 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care
    Get the next $BJDX alert in real time by email
    SC 13G 1 d850844dsc13g.htm SC 13G SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    (Amendment No. )

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

    RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

     

    BLUEJAY DIAGNOSTICS, INC.

    (Name of Issuer)

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

    095633400

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

     

     


    CUSIP No. 095633400    13G     

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Anson Funds Management LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Texas

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     319,280

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     319,280

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     319,280

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.1% **

    12  

     TYPE OF REPORTING PERSON*

     

     IA, PN

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4(b).

     

    2


    CUSIP No. 095633400    13G     

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Anson Management GP LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Texas

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     319,280

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     319,280

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     319,280

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.1% **

    12  

     TYPE OF REPORTING PERSON*

     

     HC, OO

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4(b).

     

    3


    CUSIP No. 095633400    13G     

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Tony Moore

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States Citizen

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     319,280

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     319,280

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     319,280

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.1% **

    12  

     TYPE OF REPORTING PERSON*

     

     HC, IN

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4(b).

     

    4


    CUSIP No. 095633400    13G     

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Anson Advisors Inc.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Ontario, Canada

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     319,280

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     319,280

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     319,280

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.1% **

    12  

     TYPE OF REPORTING PERSON*

     

     FI, CO

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4(b).

     

    5


    CUSIP No. 095633400    13G     

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Amin Nathoo

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Canadian Citizen

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     319,280

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     319,280

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     319,280

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.1% **

    12  

     TYPE OF REPORTING PERSON*

     

     HC, IN

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4(b).

     

    6


    CUSIP No. 095633400    13G     

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Moez Kassam

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Canadian Citizen

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     319,280

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     319,280

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     319,280

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.1% **

    12  

     TYPE OF REPORTING PERSON*

     

     HC, IN

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4(b).

     

    7


    SCHEDULE 13G

    This Schedule 13G (the “Schedule 13G”) is being filed on behalf of Anson Funds Management LP (d/b/a Anson Funds), a Texas limited partnership, Anson Management GP LLC, a Texas limited liability company, Mr. Tony Moore, the principal of Anson Funds Management LP and Anson Management GP LLC, Anson Advisors Inc., an Ontario, Canada corporation, Mr. Amin Nathoo, a director of Anson Advisors Inc., and Mr. Moez Kassam, a director of Anson Advisors Inc., relating to Common Stock, $0.0001 par value (the “Common Stock”), of Bluejay Diagnostics, Inc., a Delaware corporation (the “Issuer”).

    This Schedule 13G relates to the Common Stock of the Issuer purchased by a private fund to which Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors (the “Fund”). Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors to the Fund and may direct the vote and disposition of the 319,280 shares of Common Stock held by the Fund. As the general partner of Anson Funds Management LP, Anson Management GP LLC may direct the vote and disposition of the 319,280 shares of Common Stock held by the Fund. As the principal of Anson Fund Management LP and Anson Management GP LLC, Mr. Moore may direct the vote and disposition of the 319,280 shares of Common Stock held by the Fund. As directors of Anson Advisors Inc., Mr. Nathoo and Mr. Kassam may each direct the vote and disposition of the 319,280 shares of Common Stock held by the Fund.

     

    Item 1(a)

    Name of Issuer.

    Bluejay Diagnostics, inc.

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices.

    360 Massachusetts Avenue, Suite 203

    Acton, MA, 01720

     

    Item 2(a)

    Name of Person Filing.

    Anson Funds Management LP, Anson Management GP LLC, Mr. Tony Moore,

    Anson Advisors Inc., Mr. Amin Nathoo and Mr. Moez Kassam

     

    Item 2(b)

    Address of Principal Business Office, or, if none, Residence.

    For Anson Funds Management LP, Anson Management GP LLC and Mr. Moore:

    16000 Dallas Parkway, Suite 800

    Dallas, Texas 75248

    For Anson Advisors Inc., Mr. Nathoo and Mr. Kassam:

    181 Bay Street, Suite 4200

    Toronto, ON

    M5J 2T3

     

    8


    Item 2(c)

    Citizenship or Place of Organization.

    Anson Funds Management LP is a limited partnership organized under the laws of the State of Texas. Anson Management GP LLC is a limited liability company organized under the laws of the State of Texas. Mr. Moore is a United States citizen. Anson Advisors Inc. is a corporation organized under the laws of Ontario, Canada. Mr. Nathoo and Mr. Kassam are each Canadian citizens.

     

    Item 2(d)

    Title of Class of Securities.

    Common Stock, $0.0001 par value

     

    Item 2(e)

    CUSIP Number.

    095633400

     

    Item 3

    Reporting Person.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)    ☒    An investment advisor in accordance with §240.13d-1(b)(1)(ii)(E).
    (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
    (g)    ☒    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
    (h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)    ☐    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)    ☒    A non-U.S. institution that is the functional equivalent of any of the institutions listed in § 240.13d-1 (b)(1)(ii)(A) through (I), so long as the non-U.S. institution is subject to a regulatory scheme that is substantially comparable to the regulatory scheme applicable to the equivalent U.S. institution.
    (k)    ☐    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    9


    Item 4

    Ownership.

     

      (a)

    Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam are the beneficial owners of 319,280 shares of Common Stock held by the Fund.

     

      (b)

    Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam are the beneficial owners of 5.1% of the outstanding shares of Common Stock. This percentage is determined by dividing 319,280 by 6,252,192 shares of Common Stock issued and outstanding, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 14, 2024.

     

      (c)

    Anson Funds Management LP and Anson Advisors Inc., as the co-investment advisors to the Fund, may direct the vote and disposition of the 319,280 shares of Common Stock held by the Fund. Anson Management GP LLC, as the general partner of Anson Funds Management LP, may direct the vote and disposition of the 319,280 shares of Common Stock held by the Fund. As the principal of Anson Funds Management LP and Anson Management GP LLC, Mr. Moore may direct the vote and disposition of the 319,280 shares of Common Stock held by the Fund. Mr. Nathoo and Mr. Kassam, each as a director of Anson Advisors Inc., may direct the vote and disposition of the 319,280 shares of Common Stock held by the Fund.

     

    Item 5

    Ownership of Five Percent or Less of a Class.

    Inapplicable.

     

    Item 6

    Ownership of More Than Five Percent on Behalf of Another Person.

    See description regarding the Fund in the introduction, which is incorporated by reference herein.

     

    Item 7

    Identification and Classification of the Subsidiary which Acquired the Security Being Reported On by the Parent Holding Company.

    See description of control persons of Anson Funds Management LP and Anson Advisors Inc. in the introduction, which is incorporated by reference herein.

     

    Item 8

    Identification and Classification of Members of the Group.

    Inapplicable.

     

    Item 9

    Notice of Dissolution of Group.

    Inapplicable.

     

    Item 10

    Certification.

    By signing below each of the Reporting Persons certifies that, to the best of such person’s knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and were not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    10


    For Anson Advisors Inc.:

    By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to portfolio managers and exempt market dealers is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution. I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

    Exhibits   Exhibit 99.1

    Joint Filing Agreement dated November 14, 2024, by and among Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam.

     

    11


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: November 14, 2024

     

    ANSON FUNDS MANAGEMENT LP
    By:   Anson Management GP LLC, its general partner
    By:  

    /s/ Tony Moore

      Tony Moore
      Manager
    ANSON MANAGEMENT GP LLC
    By:  

    /s/ Tony Moore

      Tony Moore
      Manager

    /s/ Tony Moore

    Tony Moore
    ANSON ADVISORS INC.
    By:  

    /s/ Amin Nathoo

      Amin Nathoo
      Director
    By:  

    /s/ Moez Kassam

      Moez Kassam
      Director

    /s/ Amin Nathoo

    Amin Nathoo

    /s/ Moez Kassam

    Moez Kassam

     

    12

    Get the next $BJDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BJDX

    DatePrice TargetRatingAnalyst
    1/12/2022$10.00Buy
    Dawson James
    More analyst ratings

    $BJDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bluejay Diagnostics Inc.

      SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

      11/14/24 5:49:49 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bluejay Diagnostics Inc.

      SC 13G/A - Bluejay Diagnostics, Inc. (0001704287) (Subject)

      11/14/24 3:54:54 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Bluejay Diagnostics Inc.

      SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

      7/3/24 4:01:01 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dawson James initiated coverage on Bluejay Diagnostics with a new price target

      Dawson James initiated coverage of Bluejay Diagnostics with a rating of Buy and set a new price target of $10.00

      1/12/22 9:00:51 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dey Svetlana bought $1,535 worth of shares (500 units at $3.07), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:17:42 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Dey Indranil bought $1,635 worth of shares (500 units at $3.27), increasing direct ownership by 2% to 28,526 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:16:33 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dey Svetlana bought $1,535 worth of shares (500 units at $3.07), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:17:42 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Dey Indranil bought $1,635 worth of shares (500 units at $3.27), increasing direct ownership by 2% to 28,526 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:16:33 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Scally Frances P

      3 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      10/11/23 7:21:49 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BJDX
    SEC Filings

    See more
    • Bluejay Diagnostics Provides Mid-Year Business and Corporate Update

      ACTON, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient testing solutions for critical care, today provided a 2025 mid-year business and corporate update. Recent Business Highlights and Developments: SYMON Clinical Program Update: The Company has initiated its pivotal SYMON-II clinical study, following the successful completion of the SYMON-I pilot study, for which a primary analysis highlighted that IL-6 levels within 24 hours of ICU admission may predict sepsis patient mortality out to 28 days. Currently, the Company is collecting, freezing and biobanking samples, w

      6/3/25 4:05:00 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting

      ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX), today announced acceptance of an abstract related to the Symphony IL-6 Test, the company's lead product candidate, for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting, taking place in Philadelphia May 13-16, 2025. Results from SYMON-I, a pilot clinical study of interleukin-6 (IL-6) in sepsis patients intended or admitted for the intensive care unit (ICU), will be presented. SYMON-I evaluated IL-6 as a prognosticator for 28-day mortality and exploratory endpoints including 7-day mortality and microbiological positivity. "Early use of IL-6 in sepsis and septic shock pat

      4/15/25 7:00:00 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds

      ACTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the "Existing Warrants"), wherein the investors agreed to exercise the Existing Warrants to purchase up 1,085,106 shares of common stock at a reduced exercise price of $3.42 per share, resulting in gross proceeds of approximately $3.7 million, before deducting

      4/7/25 5:21:14 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Bluejay Diagnostics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

      5/28/25 5:18:49 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Bluejay Diagnostics Inc.

      DEF 14A - Bluejay Diagnostics, Inc. (0001704287) (Filer)

      5/16/25 5:00:34 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Bluejay Diagnostics Inc.

      10-Q - Bluejay Diagnostics, Inc. (0001704287) (Filer)

      5/13/25 4:01:45 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance

      ACTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay", "the Company") a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that Edwin "Ed" E. Rule, has joined the Company as Vice President Regulatory, Quality and Compliance. He will report to Neil Dey, Chief Executive Officer. Mr. Rule is a highly credentialed regulatory, quality and compliance professional with more than 15 years of industry experience. He has extensive training and expertise in medical device regulations in the U.S. and numerous international markets.

      3/28/22 7:00:00 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor

      ACTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay") a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced the appointment of Mark W. Feinberg, M.D. as Chief Medical Advisor. Dr. Feinberg will guide Bluejay's clinical development programs and provide strategic medical and scientific leadership to the Company. "I am very pleased to welcome Mark on board as Chief Medical Advisor. I believe Mark's expansive clinical background and strategic leadership skills will be invaluable as we seek to develop the Compa

      1/5/22 8:15:00 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care